Macular degeneration is a progressive eye disease that damages the macula, a small but critical area at the center of your retina responsible for sharp, detailed vision. It affects over 8 million people worldwide and is the leading cause of severe vision loss in adults over 50. The condition gradually destroys central vision, the kind you use to read, recognize faces, and drive, while leaving peripheral (side) vision intact.
Why the Macula Matters
The macula sits at the very center of the retina, the light-sensitive tissue lining the back of your eye. Within it lies a tiny pit called the fovea, only about 1.5 millimeters across, packed with the highest concentration of cone photoreceptors anywhere in the eye. These cones handle color perception and fine detail. At the fovea’s innermost point, the foveola, visual sharpness reaches its absolute peak.
This arrangement gives you the ability to thread a needle, read small print, or pick out a friend’s face in a crowd. The rest of your retina handles peripheral vision, motion detection, and low-light sight. When macular degeneration strikes, it targets this high-resolution center while leaving the surrounding retina largely unaffected. That’s why people with advanced disease can still navigate a room but can’t read a book or see the details of a face directly in front of them.
Dry vs. Wet: Two Forms of the Disease
Macular degeneration comes in two forms, classified by whether abnormal blood vessels have invaded the retina.
Dry macular degeneration accounts for roughly 80 to 90 percent of cases. It begins when small yellowish deposits called drusen accumulate beneath the retinal pigment epithelium (RPE), the support layer that nourishes the light-sensing cells above it. In early stages, these deposits cause no symptoms at all. Over time, the RPE cells and the photoreceptors they support begin to break down. The advanced stage of dry AMD is called geographic atrophy, where patches of the macula thin and die, creating permanent blind spots in central vision.
Wet macular degeneration is less common but more aggressive. It develops when immature, fragile blood vessels grow from beneath the retina upward into the macular area. These vessels leak fluid and blood, causing rapid swelling and scarring that can destroy central vision in weeks or months if untreated. Wet AMD can develop on its own or evolve from existing dry AMD.
Symptoms at Each Stage
In the early stage, most people notice nothing at all. The drusen deposits are only detectable during an eye exam. This is one reason routine eye exams matter so much for anyone over 50.
As the disease progresses to intermediate stages, vision may become blurry or slightly distorted. Straight lines, like door frames or text on a page, can start to appear wavy or bent. You might struggle more in low light, notice that colors look duller, or find it harder to adjust when moving from a bright room to a dim one.
In late-stage disease, a blank or dark spot develops in the center of your visual field. Reading, driving, and recognizing faces become difficult or impossible, depending on how much of the macula is affected. Peripheral vision typically remains, so total blindness is rare.
How It’s Detected
Eye care providers use several tools to diagnose and monitor macular degeneration. One of the simplest is the Amsler grid, a square of evenly spaced straight lines with a dot in the center. You look at the dot and note whether any lines appear wavy, broken, or missing. Significant distortion suggests macular changes and can also help track whether the disease is worsening. Your eye doctor may give you one to use at home between appointments.
The most important diagnostic tool is optical coherence tomography, or OCT. This painless, noninvasive scan creates detailed cross-sectional images of the retina, allowing your doctor to measure retinal thickness, spot fluid accumulation, and detect drusen or areas of thinning. Because it’s quick and highly reproducible, OCT is used not only for initial diagnosis but also at follow-up visits to track disease activity and guide treatment decisions. In cases of suspected wet AMD, a dye-based imaging test called fluorescein angiography may be used to reveal leaking blood vessels.
Risk Factors You Can and Can’t Control
Age is the single biggest risk factor: the condition rarely appears before 50 and becomes increasingly common with each decade after. Genetics play a substantial role as well. Variants in specific genes, particularly one called complement factor H (CFH) and another called ARMS2, significantly increase susceptibility. One rare CFH variant carries an odds ratio greater than 20, meaning carriers face an extraordinarily elevated risk. Having a parent or sibling with AMD raises your chances considerably.
Among the factors you can control, cigarette smoking stands out. Women who smoked 25 or more cigarettes per day had 2.4 times the risk of vision-threatening AMD compared to those who never smoked. Even former heavy smokers carried double the risk. Researchers estimated that roughly 29 percent of AMD cases in one large study were attributable to smoking alone. Obesity also matters: a BMI of 30 or higher was associated with approximately 2.35 times the risk of progressing to advanced disease, with a clear trend of higher risk at higher BMI levels.
The retina is also highly vulnerable to oxidative damage from light exposure and normal metabolic processes, because the photoreceptor membranes are rich in delicate fatty acids. This vulnerability is part of why nutrition and lifestyle factors play such a meaningful role in both prevention and progression.
Diet and Prevention
What you eat has a surprisingly strong connection to macular degeneration risk. A landmark 1994 study found that people with the highest intake of lutein and zeaxanthin, two carotenoid pigments concentrated in leafy greens, had a 56 percent lower risk of AMD compared to those with the lowest intake. Eating spinach, kale, or similar greens five to six times per week was associated with substantially reduced risk.
Fish matters too. Consuming two or more servings per week of fatty fish like salmon, sardines, or mackerel reduced AMD progression rates by approximately 20 percent. Overall, a Mediterranean-style dietary pattern, rich in vegetables, fish, nuts, olive oil, and minimally processed foods, reduces progression to advanced AMD by about 26 percent and slows drusen buildup in people with intermediate disease. Even for those who already have early or intermediate AMD, eating at least 2.7 servings per week of green leafy vegetables and maintaining higher lutein and zeaxanthin intake reduced the chance of worsening by 25 percent over five years.
The AREDS2 Supplement Formula
For people already diagnosed with intermediate AMD or advanced disease in one eye, a specific supplement formula tested in two major National Eye Institute clinical trials (known as AREDS and AREDS2) has been shown to slow progression. The AREDS2 formula contains vitamin C (500 mg), vitamin E (180 mg), zinc (80 mg), copper (2 mg), lutein (10 mg), and zeaxanthin (2 mg), taken daily. Copper is included because high-dose zinc can otherwise cause a copper deficiency.
These supplements are not a cure and don’t restore lost vision. They’re designed to reduce the odds of intermediate dry AMD progressing to advanced stages. They’re not recommended for people with no signs of the disease or only very early changes. Your eye care provider can tell you whether you’re at a stage where this formula would be beneficial.
Treatment for Wet AMD
Wet macular degeneration is treated with injections of medications that block a protein called vascular endothelial growth factor, or VEGF. This protein drives the growth of those abnormal, leaky blood vessels. By blocking it, the injections can stop leaking, reduce swelling, and in many cases improve vision. The procedure involves numbing the eye with drops and delivering a tiny injection directly into the eye’s gel-filled interior. It sounds alarming, but most patients describe it as pressure rather than sharp pain.
Several medications are currently used. Ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo) were designed specifically for eye conditions. Bevacizumab (Avastin), originally a cancer drug, is widely used off-label at lower cost. The two newest options, Vabysmo and a higher-dose version called Eylea HD, allow some patients to space injections to three or four times per year instead of the six to twelve visits older treatments often require. Finding the right interval for each patient is an ongoing process that depends on how the eye responds.
Treatment for Advanced Dry AMD
For decades, there was no treatment for geographic atrophy, the advanced stage of dry AMD. That changed in 2023 when the FDA approved two new medications, both targeting part of the immune system’s complement pathway, which contributes to the progressive destruction of retinal cells. Pegcetacoplan (Syfovre) was approved in February 2023, followed by avacincaptad pegol (Izervay) later that year.
Both are delivered by injection into the eye, similar to wet AMD treatments. They don’t reverse damage that’s already occurred, but they slow the rate at which the atrophy expands, potentially preserving remaining vision for longer. This represents a meaningful shift for a form of the disease that was previously managed only with supplements and monitoring.